Research
And Grants
Note: When clicking the "Submit Grant Application" button below you will be redirected to SnapGrant.com to complete the application process.
Submit Grant ApplicationNote: All Grants Are U.S. Funded Through 2018
CONNECT Consortium - $489,801.26
$489,801.00 USD
September 2020
CONNECT (COllaborative Network for NEurooncology Clinical Trials) Consortium
International DIPG/DMG Registry And Repository - $862,671
$862,671.00 USD
May 2020
Funding of PBTCF 2020: PBTC-058 - $25,000
$25,000.00 USD
January 2020
PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma
Sydney Children's Hospital - $151,468 USD / $219,386 AUD (Approx)
$151,468.00 USD
December 2019
Developing New Epigenetic Combination Treatments Against DIPG.
Oncoceutics ONC201 - $100,000
$100,000.00 USD
December 2019
Expansion of the ONC201 Compassionate Use.
University of Sydney - $100,000 USD / $146,520 AUD (Approx)
$100,000.00 USD
November 2019
Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an approach of radiosensitization for diffuse intrinsic pontine gliomas.
University of Michigan Hospitals - $157,856
$157,856.00 USD
November 2019
Therapeutic reversal of pre-natal pontine ID1 signaling in DIPG
Dayton Children's Hospital - $69,600
$69,600.00 USD
November 2019
Responses of distinct cell populations to PDGFRA inhibitors in diffuse intrinsic pontine glioma.
Institute of Cancer Research - $121,863
$121,863.00 USD
November 2019
Targeting Top3A-Amplified DIPG cells by Sirtuin inhibition.
Bambino Gesu Children's Hospital - $49,803
$49,803.00 USD
August 2019
Using imaging mass cytometry to identify next generation imaging biomarkers in PHGG and DIPG.
Telethon Kids Institute - $49,512 USD / $69,822 AUD (Approx)
$49,512.00 USD
August 2019
Development of a new and effective therapy against Diffuse Intrinsic Pontine Glioma.
Oncoceutics ONC201 - Phase II - $83,333
$83,333.00 USD
May 2019
Expansion of the ONC201 Compassionate Use.
Funding of PBTCF 2019: PBTC-058 - $25,000
$25,000.00 USD
January 2019
PBTC-058: Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma
Sydney Children’s Hospital - $175,089 USD / $242,388 AUD (Approx)
$175,089.00 USD
November 2018
Polyamine Pathway Metabolism as a Novel Therapeutic Option for Diffuse Intrinsic Pontine Glioma
Cincinnati Children's Hospital - $540,742
$540,742.00 USD
November 2018
Expansion of the International DIPG Registry.